收藏切换
Signal mining and analysis of adverse events associated with trastuzumab deruxtecan based on WHO-VigiAccess and FAERS databases
收藏切换
Xin ZHAO, Susu LI, Zengqing MA, Lianping WU, Guoping SUN*
World Clinical Drug | 2025, 46(11) : 1163 - 1171
Less
收藏切换
World Clinical Drug | 2025, 46(11): 1163-1171
• Article •
Signal mining and analysis of adverse events associated with trastuzumab deruxtecan based on WHO-VigiAccess and FAERS databases
Full
Xin ZHAO, Susu LI, Zengqing MA, Lianping WU, Guoping SUN*
Affiliations
  • Department of Pharmacy, Gaochun Hospital Affiliated to Jiangsu University, Nanjing 211300, Jiangsu Province, China
Published: 2025-11-10 doi: 10.13683/j.wph.2025.11.012
Outline
收藏切换
Objective

To investigate and analyze the adverse event (AE) signals associated with trastuzumab deruxtecan, and provide scientific basic for clinical use and regulatory decision-making.

Methods

AE reports related to trastuzumab deruxtecan from its market launch to Nov 24, 2024, were retrieved from the WHO-VigiAccess and FAERS databases. Disproportionality analysis methods, including reporting odds ratio, proportional reporting ratio, and Bayesian confidence propagation neural network, were used for signal detection.

Results

A total of 12 545 reports from WHO-VigiAccess and 5 924 reports from the FAERS database related to trastuzumab deruxtecan were included. A total of 243 significant AE signals were identified, involving 20 system organ classification, with a focus on general disorders and administration site reactions, gastrointestinal disorders, respiratory, thoracic and mediastinal disorders, and blood and lymphatic system disorders. Additionally, 114 new potential risk signals were detected (accounting for 46.91%), including weight gain, ascites, pleural effusion, sepsis, pulmonary embolism, and PJP.

Conclusion

Continuous monitoring of drug safety is essential during trastuzumab deruxtecan therapy to maximize therapeutic outcomes and minimize risks.

trastuzumab deruxtecan  /  adverse drug events  /  signal mining  /  pharmacovigilance  /  medication safety
赵欣, 李素素, 马曾庆, 吴连平, 孙国平. 基于WHO-VigiAccess和美国FAERS数据库的德曲妥珠单抗不良事件信号挖掘与分析. 世界临床药物, 2025 , 46 (11) : 1163 -1171 . DOI: 10.13683/j.wph.2025.11.012
Xin ZHAO, Susu LI, Zengqing MA, Lianping WU, Guoping SUN. Signal mining and analysis of adverse events associated with trastuzumab deruxtecan based on WHO-VigiAccess and FAERS databases[J]. World Clinical Drug, 2025 , 46 (11) : 1163 -1171 . DOI: 10.13683/j.wph.2025.11.012
Year 2025 volume 46 Issue 11
55
10
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2025.11.012
  • Receive Date:2025-05-13
  • Online Date:2026-11-09
  • Published:2025-11-10
Article Data
Affiliations
History
  • Received:2025-05-13
Funding
Affiliations
    Department of Pharmacy, Gaochun Hospital Affiliated to Jiangsu University, Nanjing 211300, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.11.012
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT